Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Show less

Author information

Affiliations

  • 1. From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).
      Authors
    • Kopetz S 1
    • Grothey A 1
    • Yaeger R 1
    • Van Cutsem E 1
    • Desai J 1
    • Yoshino T 1
    • Wasan H 1
    • Ciardiello F 1
    • Loupakis F 1
    • Hong YS 1
    • Steeghs N 1
    • Guren TK 1
    • Arkenau HT 1
    • Garcia-Alfonso P 1
    • Pfeiffer P 1
    • Orlov S 1
    • Lonardi S 1
    • Elez E 1
    • Kim TW 1
    • Schellens JHM 1
    • Guo C 1
    • Krishnan A 1
    • Dekervel J 1
    • Morris V 1
    • Calvo Ferrandiz A 1
    • Tarpgaard LS 1
    • Braun M 1
    • Gollerkeri A 1
    • Keir C 1
    • Maharry K 1
    • Pickard M 1
    • Christy-Bittel J 1
    • Anderson L 1
    • Sandor V 1
    • Tabernero J 1
    (35 authors)

ORCIDs linked to this article

Show all (10)

The New England Journal of Medicine, 30 Sep 2019, 381(17):1632-1643
https://doi.org/10.1056/nejmoa1908075 PMID: 31566309 

A comment on this article appears in "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer." N Engl J Med. 2020 Feb 27;382(9):876. A comment on this article appears in "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer." N Engl J Med. 2020 Feb 27;382(9):876. A comment on this article appears in "Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer." N Engl J Med. 2020 Feb 27;382(9):876-877. Show all (4)

Abstract 

Background

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.

Methods

In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E-mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators' choice of either cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan) (control group). The primary end points were overall survival and objective response rate in the triplet-therapy group as compared with the control group. A secondary end point was overall survival in the doublet-therapy group as compared with the control group. We report here the results of a prespecified interim analysis.

Results

The median overall survival was 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95% confidence interval [CI], 0.39 to 0.70; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group and 2% (95% CI, 0 to 7) in the control group (P<0.001). The median overall survival in the doublet-therapy group was 8.4 months (hazard ratio for death vs. control, 0.60; 95% CI, 0.45 to 0.79; P<0.001). Adverse events of grade 3 or higher occurred in 58% of patients in the triplet-therapy group, in 50% in the doublet-therapy group, and in 61% in the control group.

Conclusions

A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation. (Funded by Array BioPharma and others; BEACON CRC ClinicalTrials.gov number, NCT02928224; EudraCT number, 2015-005805-35.).

Full text links 

Read article at publisher's site: https://doi.org/10.1056/nejmoa1908075

Citations & impact 

Impact metrics

587
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/67468536
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/67468536

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1056/nejmoa1908075

Supporting
Mentioning
Contrasting
19
800
4

Article citations

Go to all (587) article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

Clinical Trials

European Clinical Trials

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Array BioPharma